This Monday, the pharmaceutical laboratory Merck officially submitted a request to the Food and Drug Administration (FDA) for their authorization of emergency use for their medicine molnupiravir, which according to their research, is an effective antiviral treatment against Covid-19.
In its office, Merck pointed out that molnupirvair (in capsule presentation) it is highly effective in treating adults who have been infected with coronavirus and that for multiple reasons, they have a great chance of developing serious complications or ending up admitted to the hospital.
This statement is supported by an in-depth analysis carried out over several weeks in which the behavior of 700 patients with Covid, none vaccinated, and their evolution after taking the drug were observed.
“In the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%. 7.3% of the patients who received molnupiravir were hospitalized or died until day 29 after randomization, compared with 14.1% of the patients treated with placebo, “the pharmacist said in a statement.
“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” said the Merck CEO and President Robert Davis in the statement.
What is Merck’s molnupiravir treatment for Covid-19?
The recommended dose of molnupiravir to treat Covid consists of 4 pills of 200 mg that must be taken 2 times a day for 5 days. In total, the complete treatment requires taking 40 pills.
Such treatment would cost the United States government around $ 700 and it is known that it has already purchased nearly 1.7 million treatments at a cost of $ 1.2 million.
However, Merck assured that it has not yet been able to set a price for molnupiravir for the general public since they still do not have official approval for its use, for which, the pharmaceutical company will continue to do some research to be able to assess it, also taking into account the economies of each country and the costs they have had to overcome the pandemic.
In case the FDA gives its authorization, the drug manufactured by Merck and Ridgeback Biotherapeutics would be the first oral antiviral treatment to combat Covid.
It may interest you:
Pfizer tests anticovid pill for patients with symptoms that do not require hospitalization
The race to create a pill against Covid-19 accelerates the pace
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.